Orris

I am Nephrology resident.... Teach me adpkd

Reading File
Reading File
Searching the Web

ADPKD KDIGO 2025 guideline diagnosis management tolvaptan

Finding Sources
Finding Sources
Finding Sources
Searching PubMed

"polycystic kidney diseases"[MeSH Terms] AND treatment

Reading Web Page

https://kdigo.org/wp-content/uploads/2025/01/KDIGO-2025-ADPK…

Reading File
Reading File
Finding Sources
Reading Web Page

https://kdigo.org/wp-content/uploads/2025/01/KDIGO-2025-ADPK…

ADPKD: a nephrology-resident approach

Autosomal dominant polycystic kidney disease (ADPKD) is a systemic, inherited ciliopathy characterized by progressive bilateral renal cyst formation, kidney enlargement, hypertension, CKD, and extrarenal disease. It is usually caused by a pathogenic variant in PKD1 or PKD2. Each child of an affected individual has a 50% risk. PKD1 generally has earlier and more severe kidney disease than PKD2. - Brenner and Rector’s The Kidney, p. 1983
The current practical framework is the KDIGO 2025 ADPKD guideline.

1. Pathobiology you need to understand

The two-hit model

  • Germline heterozygous pathogenic variant in PKD1 (polycystin-1) or PKD2 (polycystin-2).
  • A somatic “second hit” in a tubular epithelial cell permits focal cyst initiation.
  • Cysts arise from different nephron segments, detach, and enlarge through:
    • epithelial proliferation
    • chloride and fluid secretion into the cyst
    • interstitial inflammation/fibrosis
    • vasopressin-driven cAMP signaling
    • altered ciliary mechanosensation and Ca²⁺ signaling.

Why vasopressin matters

V2 receptor activation increases cAMP in cyst epithelia, promoting secretion and growth. Tolvaptan, a selective V2 antagonist, slows kidney enlargement and loss of eGFR in people likely to progress rapidly.

2. When should you suspect ADPKD?

Typical clues:
  • Bilateral, multiple renal cysts with enlarged kidneys
  • Positive family history
  • Early hypertension, often before a fall in eGFR
  • Flank or abdominal fullness/pain
  • Gross or microscopic hematuria
  • Nephrolithiasis
  • Hepatic cysts, especially in women and with increasing age
  • Intracranial aneurysm or family history of aneurysmal SAH
  • “CKD of uncertain cause” in a patient with cystic kidneys
Remember that roughly 10%-20% of cases may appear de novo, so absence of a family history does not exclude ADPKD.

3. Establishing the diagnosis

A. First-line: kidney ultrasound in an at-risk person

For an individual with an affected first-degree relative, commonly used unified ultrasound criteria are:
AgeDiagnosis supported by
15-39 years≥3 total renal cysts, unilateral or bilateral
40-59 years≥2 cysts in each kidney
≥60 years≥4 cysts in each kidney
A negative ultrasound is more reliable for excluding disease after age 40. In younger individuals, especially possible PKD2, ultrasound can miss early disease.

B. MRI or CT

Use when:
  • ultrasound is equivocal
  • disease is atypical
  • a precise total kidney volume is required
  • evaluating a potential living donor
  • assessing a young at-risk individual with negative/equivocal ultrasound.
MRI is preferred for measuring TKV because it avoids radiation and is the basis for the Mayo Imaging Classification.

C. Genetic testing

Not mandatory in a typical phenotype plus family history. It is useful when:
  • phenotype is atypical or family history absent
  • imaging is equivocal
  • early exclusion is required in a potential living donor
  • reproductive planning or preimplantation genetic testing is being considered
  • severe/early-onset disease suggests digenic disease or an alternative cystic disorder.
Testing needs a cystic-kidney gene panel and expert variant interpretation. PKD1 is technically difficult because of pseudogenes. KDIGO emphasizes that genetics can diagnose and provide prognostic information, but is not necessary for initial diagnosis in a typical presentation. KDIGO guidance

4. Differential diagnosis of bilateral cystic kidneys

Do not label every cystic kidney as ADPKD.
  • Simple renal cysts, especially with age
  • Acquired cystic kidney disease in advanced CKD/dialysis: kidneys are usually small or normal-sized, not massively enlarged
  • Autosomal recessive PKD
  • HNF1B-related disease
  • Tuberous sclerosis complex/PKD1 contiguous-gene syndrome
  • AD tubulointerstitial kidney disease
  • VHL disease
  • Multiple simple cysts or other genetic cystic diseases.
Typical ADPKD morphology: diffuse bilateral cyst distribution and symmetric enlargement, often with liver cysts.
Atypical morphology: asymmetric, segmental, unilateral, lopsided, or atrophic patterns. Do not apply Mayo imaging risk classes blindly to atypical disease.

5. Prognosis: identify rapid progressors early

This is the central clinic task because it determines who may benefit from tolvaptan.

A. Mayo Imaging Classification

Use height-adjusted total kidney volume (htTKV) and age in patients with typical ADPKD morphology.
  • Class 1A and 1B: low likelihood of rapid progression
  • Class 1C: intermediate. Some are rapid progressors, particularly at younger ages or with supportive evidence.
  • Class 1D and 1E: high likelihood of rapid progression
  • Class 2: atypical morphology, so Mayo class-based prediction is not valid.
In practice, 1D/1E strongly support disease-modifying treatment if otherwise eligible. For 1C, seek corroborating evidence.

B. Evidence that supports rapid progression

  • Sustained historical eGFR decline, typically ≥3 mL/min/1.73 m²/year
  • Mayo class 1C-1E, especially 1D/1E
  • PROPKD score >6, which incorporates sex, early hypertension, early urologic events, and genotype
  • Truncating PKD1 variant
  • Early-onset hypertension, hematuria, stones, or urologic events
  • Marked kidney enlargement for age.

Resident pitfall

A “stable” eGFR in a 25-year-old does not mean stable disease. Hyperfiltration and renal reserve may conceal structural progression. Use age, htTKV, genotype, and longitudinal trajectory.

6. Disease-modifying therapy: tolvaptan

KDIGO recommends considering tolvaptan in adults with:
  • ADPKD,
  • eGFR ≥25 mL/min/1.73 m², and
  • evidence/risk of rapidly progressive disease. KDIGO recommendation

Dosing

A usual split-dose approach:
  • Start 45 mg on waking + 15 mg about 8 hours later
  • Titrate, if tolerated, toward 90 mg + 30 mg.
The short interval between doses provides stronger daytime V2 blockade while reducing overnight polyuria.

Counseling before prescribing

A patient should understand:
  • marked aquaresis, polyuria, nocturia, thirst
  • need to drink to thirst and maintain access to water
  • sick-day management and dehydration risk
  • temporary interruption when unable to maintain water intake
  • avoidance in pregnancy and lactation
  • interaction review, especially strong CYP3A inhibitors/inducers
  • liver monitoring is mandatory.

Liver monitoring

Follow the locally approved protocol. A typical schedule is:
  • baseline ALT/AST/bilirubin
  • at 2 and 4 weeks after initiation
  • monthly for the first 18 months
  • then every 3 months while on therapy.
Tolvaptan must be withheld and evaluated promptly for significant transaminitis or symptoms of liver injury.

Practical monitoring in clinic

At initiation and titration:
  • BP, weight, symptoms, volume status
  • serum sodium, creatinine/eGFR
  • liver tests per protocol
  • adherence, urine volume/nocturia, work and driving implications
  • concomitant diuretics and other dehydration-promoting drugs.
Recent evidence synthesis supports tolvaptan as the best-established pharmacologic option to slow ADPKD progression, while certainty for many other interventions remains limited. See the 2024 Cochrane review.

7. Core supportive management

A. Blood pressure

Hypertension is often the earliest treatable manifestation and contributes to CV risk and kidney progression.
  • Use ACE inhibitor or ARB as first-line in most patients, especially with albuminuria.
  • Avoid routine ACEi plus ARB dual blockade.
  • Encourage home BP monitoring.
For adults aged 18-49 years with BP >130/85 mm Hg and preserved kidney function, intensive targets around ≤110/75 mm Hg, if tolerated, are supported by ADPKD-specific evidence. In older patients or those unable to tolerate this, individualize treatment, often following general CKD targets.

B. Sodium and lifestyle

  • Sodium restriction, generally <2 g sodium/day or <5 g salt/day.
  • Healthy weight, regular physical activity, smoking cessation.
  • Avoid very high protein intake. A normal recommended protein intake is reasonable unless another CKD indication exists.
  • Avoid NSAIDs when possible, especially with CKD, hypertension, RAAS blockade, or volume depletion.

C. Water intake

Avoid chronic dehydration. Increased water intake is reasonable in those with low baseline intake, but it is not a substitute for tolvaptan in a rapid progressor. Avoid forcing water to the point of hyponatremia. Individualize in advanced CKD, heart failure, or hyponatremia risk.

D. Cardiovascular risk

Treat diabetes, dyslipidemia, obesity, and smoking as in other CKD populations. Albuminuria is not usually prominent in uncomplicated ADPKD. Significant proteinuria should prompt consideration of superimposed glomerular disease.

8. Common renal complications

Hematuria

Most commonly due to:
  • cyst hemorrhage
  • stone
  • infection
  • less commonly malignancy.
Typical cyst hemorrhage causes sudden flank pain with gross hematuria and settles within days.
Red flags requiring further work-up
  • persistent or recurrent hematuria
  • constitutional symptoms
  • obstruction/clots
  • older age, smoking history, or cancer risk
  • atypical imaging findings.

Cyst infection

Suspect with:
  • fever
  • persistent localized flank or abdominal pain
  • elevated CRP/inflammatory markers
  • often negative urine culture, because the infected cyst may not communicate with the collecting system.
Blood and urine cultures should be obtained, but negative cultures do not exclude it.
Imaging:
  • CT/MRI may help but can be non-diagnostic.
  • FDG-PET/CT can be useful when diagnosis/localization remains uncertain.
Antibiotics need adequate cyst penetration. Selection should reflect local resistance, kidney function, culture data, interactions, and adverse-effect profile. Persistent fever or relapse raises concern for resistant infection, incorrect source, obstructed system, or a cyst requiring drainage.

Stones

Frequency is increased. Calcium oxalate and uric acid stones are common. Evaluate with low-dose noncontrast CT if needed, use standard metabolic assessment where appropriate, and account for distorted anatomy when planning intervention.

Chronic pain

Rule out:
  • cyst hemorrhage/infection
  • stone/obstruction
  • renal or hepatic mass
  • musculoskeletal causes.
Use a stepwise approach: reassurance and conservative analgesia, specialist pain care if chronic, then selective cyst procedures or surgical options only for well-localized, refractory symptoms.

9. Extrarenal disease

Polycystic liver disease

The most frequent extrarenal manifestation.
  • Often asymptomatic.
  • Severity is more common in women, with estrogen exposure and multiple pregnancies.
  • Liver function is usually preserved despite large volume disease.
  • Treat symptoms from mass effect rather than cyst count alone.
Refer to hepatology/interventional radiology/surgery for disabling symptoms, dominant treatable cysts, infection, portal hypertension, or severe malnutrition/compression.

Intracranial aneurysm

Do not screen every ADPKD patient routinely.
Screen with time-of-flight MR angiography without gadolinium when there is:
  • personal history of subarachnoid hemorrhage
  • family history of intracranial aneurysm, aneurysmal SAH, or unexplained sudden death
  • selected high-risk occupation or major anxiety after informed discussion
  • often, evaluation before transplantation or major surgery may prompt individualized discussion.
If high-risk and initially negative, repeat screening can be individualized, commonly after 5-10 years. Control BP and avoid smoking.

Cardiac/vascular

Mitral valve prolapse, aortic root dilation, and other vascular abnormalities occur, but routine broad screening without a clinical or family-history signal is not generally indicated.

10. Pregnancy and reproductive counseling

Discuss this early, not when eGFR is already falling.
  • Autosomal dominant transmission risk is 50% per pregnancy.
  • Offer genetic counseling, including prenatal testing and preimplantation genetic testing where appropriate.
  • Stop tolvaptan before conception and avoid it during pregnancy and lactation.
  • Review ACEi/ARB before pregnancy.
  • Hypertension, proteinuria, and reduced kidney function increase maternal and fetal risk.
  • ADPKD pregnancies have increased preeclampsia risk. KDIGO advises close BP, kidney function, proteinuria, and UTI surveillance during pregnancy. Pregnancy guidance

11. Kidney failure, dialysis, and transplant

  • Preemptive transplantation is preferred when feasible.
  • Living donation is excellent, but potential related donors require careful exclusion of ADPKD.
  • Native nephrectomy is not routine before transplant.
Consider nephrectomy only for:
  • recurrent severe cyst infection or bleeding
  • intractable pain
  • symptomatic massive kidneys
  • suspected malignancy
  • inadequate space for an allograft.
Dialysis modality is individualized. Large kidneys/liver can make peritoneal dialysis mechanically challenging, but PD is not automatically contraindicated.

12. A practical first-visit ADPKD template

  1. Confirm phenotype
    • family pedigree over 3 generations
    • kidney and liver imaging
    • serum creatinine/eGFR, urinalysis, UACR
    • BP, ideally home readings.
  2. Assess complications
    • pain, hematuria, stones, UTIs/cyst infection
    • liver symptoms
    • family history of aneurysm/SAH/sudden death
    • pregnancy and reproductive plans.
  3. Stratify progression
    • obtain MRI htTKV and Mayo class if appropriate
    • chart eGFR trajectory
    • consider genetics/PROPKD when uncertainty remains.
  4. Treat
    • BP and sodium management
    • CKD and CV risk care
    • decide on tolvaptan through shared decision-making.
  5. Surveillance
    • eGFR, electrolytes, UACR, BP, symptoms at least annually, more often with CKD or therapy
    • liver tests on the mandated tolvaptan schedule
    • repeat imaging for a defined clinical reason, not automatically at every visit.

High-yield takeaways

  • Diagnosis is clinical plus imaging in a typical family phenotype. Genetics resolves atypical or uncertain cases.
  • Kidney size predicts before eGFR falls. Use MRI-based Mayo classification in typical disease.
  • Tolvaptan is for rapid progressors, not simply for anyone with cysts.
  • BP control and sodium restriction are foundational.
  • Fever plus focal pain in ADPKD is a cyst infection until proven otherwise, even if urine culture is negative.
  • Screen for intracranial aneurysm selectively, based mainly on personal and family risk.
  • Start reproductive counseling and transplant planning early.
This is a shared conversation. Sign in to Orris to start your own chat.